Is Biodesix, Inc. (BDSX) a Buy, Sell, or Hold?
Biodesix, Inc.
NASDAQ:BDSX
$21.13 USD
-$0.29 (-1.35%)
- Volume
- 56.73K
- Average Volume
- 75.88K
- Market Capitalization
- $172M
- P/E Ratio
- -5.20
- Dividend Yield
- 0.00%
- Price Target
- $27.00
- Year High
- $24.92
- Year Low
- $5.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.82
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Scott Hutton |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | BDSX |
| CUSIP | 09075X207 |
| CIK | 0001439725 |
| Web | https://www.biodesix.com |
| Phone | 303 417 0500 |
| Currency | USD |
| Employees | 334 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 7.84 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.82 |
| Quick Ratio | 2.82 |
| Cash Ratio | 1.76 |
Sales & Book Value
| Annual Sales | $88.5M |
| Price / Sales | 1.79 |
| Cash Flow | -2.61 |
| Price / Cash Flow | -6.81 |
| Price / Book | 22.34 |
Price Target and Rating
| Average Stock Price Forecast | $27.00 |
| High Stock Price Forecast | $32.00 |
| Low Stock Price Forecast | $26.00 |
| Forecast Upside/Downside | -21.74% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.67 |
| Trailing P/E Ratio | -5.20 |
| PEG Ratio | -0.14 |
| P/E Growth | -0.14 |
| Net Income | $-35.26M |
| Net Margin | -33.26% |
| Pretax Margin | -33.26% |
| Return on Equity | -2101.40% |
| Return on Assets | -33.77% |
Financials Score
| AltmanZ Score | -5.74 |
| Piotroski Score | 4.00 |
| Working Capital | 26.42M |
| Total Assets | 94.64M |
| Ebit | -23.95M |
| Market Cap | 174.36M |
| Total Liabilities | 85.5M |
Poll Results
About Biodesix, Inc. (NASDAQ:BDSX) Stock
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Gener ... ation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
2026-06-19 05:31:02
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
2026-06-15 10:41:24
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
2026-06-08 09:26:27
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
2026-05-25 10:56:09
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biodesix to Participate in Upcoming Investor Conferences
2026-05-21 06:00:00
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences:
2026-05-11 09:17:00
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
2026-05-07 10:55:31
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
2026-05-04 19:53:23
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Biodesix, Inc. (BDSX) stock price?
-
Biodesix, Inc.(NASDAQ:BDSX) stock price is $21.13 in the last trading session. During the trading session, BDSX stock reached the peak price of $24.915 while $5.26 was the lowest point it dropped to. The percentage change in BDSX stock occurred in the recent session was --1.35% while the dollar amount for the price change in BDSX stock was -$-0.29.
-
BDSX's industry and sector of operation?
-
The NASDAQ listed BDSX is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of BDSX?
-
Robin Harper Cowie | Chief Financial Officer, Secretary & Treasurer
Scott Hutton | President, Chief Executive Officer & Director
Kieran O'Kane | Chief Commercial Officer
Gary Anthony Pestano | Chief Scientific Officer
Heinrich Roder D.Phil | Founder & Chief Technology Officer -
How many employees does BDSX have?
-
Number of BDSX employees currently stands at 334. BDSX operates from 2970 Wilderness Place, Boulder, CO 80301, US.
-
Link for BDSX official website?
-
Official Website of BDSX is: https://www.biodesix.com
-
How do I contact BDSX?
-
BDSX could be contacted at phone #303 417 0500 and can also be accessed through its website. BDSX operates from 2970 Wilderness Place, Boulder, CO 80301, US.
-
How many shares of BDSX are traded daily?
-
The average number of BDSX shares traded daily for last 3 months was 75.88K.
-
What is the market cap of BDSX currently?
-
The market value of BDSX currently stands at $172M with its latest stock price at $21.13